A+ R A-

IWWM-10 Posters: W40 - W79

The following abstracts represent Posters W40-W79 that were presented at IWWM-10 (NYC-2018) Poster Session. "ORAL" signifies a 10-minute oral presentation was given during the poster session.

Session Chairs: Ranjana Advani (USA) and Marvin Stone (USA)

W40: Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies in Non-Hodgkin Lymphoma R. Booher, USA

W41: Therapeutic disruption of Bcl-2 in Conjunction with blocking CD38 results in mitochondrial collapse and apoptosis of Waldenström Macroglobulinemia tumor cells S. Ahmed, USA

W42: High-Dose Therapy and Stem Cell Transplantation in Transformed Waldenstrom Macroglobulinemia E. Durot, France

W43: CANOMAD: clinical, biological, electrophysiological and treatment analyses in 44 patients. A French retrospective study of the FILO group M. Le Cann, France

W44: Waldenström's Macroglobulinemia (WM) Clinical Trials in the United States (U.S.0: Characteristics and Disparities Over Two Decades P. Jani, USA

W45: Structurally novel curcumin analogs show tumor-specific cytoxicity in preclinical models of Waldenström Macroglobulinemia M. Iqbal, USA

W46: Dual-affinity BTK/PI3Ky overcome ibrutinib-resistance in preclinical models of Waldenstrom Macroglobulinemia M. Iqbal, USA

W47: CXCR4 mutations have no survival impact on Waldenstrom's Macroglobulinemia patients under Bortezomib-based treatment R. Sklavenitis-Pistofidis, USA

W48: Ibrutinib decreases the apoptotic threshold of Waldenström macroglobulinemia (WM) cells rendering them vulnerable to venetoclax A Manna, USA

W49: Concurrent targeting of the proteasome (ixazomib) and BTK (ibrutinib) is highly toxic inducing apoptosis through mitochondrial disruption and Bcl-2/BCR downregulation in Waldenström Macroglobulinemia cells A Manna, USA

W50: Targeting IRAK4 and PI3Kα/δ induces synergistic cell death in ibrutinib-resistant Waldenström macroglobulinemia cells A Manna, USA

W51: Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: outcomes outside of clinical trial setting J. Abeykoon, USA

W52: Clinical presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenström Macroglobulinemia J. Abeykoon, USA

W53: A novel patient-derived xenograft (PDX) model of Richter's transformed Waldenström macroglobulinemia A Sonikpreet, USA

W54: Pre-clinical high-throughput drug screening identifies novel therapeutics in Ibrutinib-resistant Bing-Neel cells A Sonikpreet, USA

W55: Development of pre-clinical model of Bing-Neel syndrome A Sonikpreet, USA

W56: Dual targeting of B5 and B1i-proteasome catalytic sub-unites is lethal to Waldenstrom macroglobulinemia cells: Therapeutic implication through novel drug candidates S. Akhtar, USA

W57: Restructuring Bcl-2 family protein interactions to overcome deferred apoptosis in Waldenstrom macroglobulinemia tumor cells: A novel role for targeting Mcl-1 A Sharma, USA

W58: IgM associated Light Chain (AL) Amyloidosis: Clinical, Genomic and Bone Marrow Pathology Features S. Sidana, USA

W59: Sustained efficacy of Ibrutinib over 30 months in Bing-Neel Syndrome E. Hatjiharissi, Greece

W60: Histological transformation in Waldenström macroglobulinemia S. Zanwar, USA

W61: Bing Neel Syndrome in Waldenström macroglobulinemia S. Zanwar, USA

W62: Waldenström macroglobulinemia with excess plasma cells: Is it a distinct entity? S. Zanwar, USA

W64: Ibrutinib for the treatment of Bing Neel Syndrome G. Itchaki, Israel

W65: The impact of CXCR4 mutation subtypes in the response and progression-free survival of patients with Waldenstrom macroglobulinemia treated with ibrutinib J. Castillo, USA

W66: Low Levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinemia J. Castillo, USA

W67: Ibrutinib Withdrawal Symptoms in Patients with Waldenström Macroglobulinemia J. Castillo, USA

W68: Low Risk of pneumocystis jiroveci Pneumonia in Patients with Waldenstrom Macroglobulinemia on Ibrutinib M. Cheng, USA

W69: Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia A Babwah, USA

W70: Evidence for clonal cooperativity in BTK Cys481Ser driven Ibrutinib resistance in Waldenström's Macroglobulinemia J. Chen, USA

W71: Mutated MYD88 cross-talk to BCR signaling through activating SYK kinase in Waldenström's Macroglobulinemia M. Munshi, USA

W72: Histological transformation in WM/LPL: absence of MYC rearrangements and rare clonally unrelated events R. Owen, United Kingdom

W73 ORAL: Significance of residual neoplastic B-cells by flow cytometry following treatment in the R2W trial R. de Tute, United Kingdom

W74: Impaired plasma cell differentiation on Waldenstrom macroglobulinemia B-cells following TLR stimulation J. Shrimpton, United Kingdom

W75: Dysregulation of B-Cell Receptor Pathway Genes Through Alternative Splicing in Waldenstrom's Macroglobulinemia N. Tsakmaklis, USA

W76: Alternative Mutations and Isoform Dysregulation in MYD88 Waldenstrom's Macroglobulinemia A Kofides, USA

W77: Comparative genomic analysis of Waldenstrom's macroglobulinemia cell lines G. Chan, USA

W78: TIR8 (SIGIRR) is suppressed in WM, and may contribute to MYD88/TLR pro-survival signaling in WM M. Demos, USA

W79: Deregulated expression of PTBPs are associated with altered splicing in Myeloma (MM) and Waldenstrom's macroglobulinemia (WM) S. Adamia, USA

Amsterdam 2016 (IWWM-9)

Amsterdam 2016 Organizers

  • MJ Kersten MD, Ph.D (U. Amsterdam)
  • Monique Minnema MD, Ph.D (UMC Utrecht)
  • Steven Pals MD, Ph.D (U. Amsterdam)
  • Steven Treon MD, Ph.D (Dana-Farber)
  • Chris Patterson - Secretariat (Dana-Farber)

The Amsterdam 2016 Scientific Committee members:

Stephen Ansell MD, PhD (USA)
Christian Buske MD, PhD (Germany)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Xavier Leleu MD, PhD (France)
Mary McMaster MD, PhD (USA)
Giampaolo Merlini MD (Italy)
Monique Minnema MD, PhD (Netherlands)
Enrica Morra MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Linda Pilarski PhD (Canada)
Steven Treon MD PhD (USA)

Click here to download the preliminary program agenda for the 9th International Workshop on WM (IWWM-9).

Registration is closed for this event.

Amsterdam 2016 (IWWM-9) was held at the Renaissance Hotel in Amsterdam.

Renaissance Hotel Amsterdam

Please enjoy this interactive sightseeing map of Amsterdam:

Interactive Map of Amsterdam

New York 2018 (IWWM-10)

New York 2018 Conference Chairs

  • Jorge Castillo, MD (Dana-Farber)
  • Richard Furman, MD (Cornell University)
  • M. Lia Palomba, MD (Memorial Sloan Kettering)
  • Steven Treon, MD, PhD (Dana-Farber)
  • Chris Patterson - Secretariat (Dana-Farber)

The New York 2018 Scientific Committee members:

Ranjana Advani, MD (USA)
Jorge Castillo MD (USA)
Meletios Dimopoulos MD (Greece)
Ramón García-Sanz MD, PhD (Spain)
Zachary Hunter, PhD (USA)
Efstathios Kastritis, MD, PhD (Greece)
Marie Jóse Kersten MD, PhD (Netherlands)
Douglas E Joshua AM (Australia)
Véronique Leblond MD (France)
Giampaolo Merlini MD (Italy)
Roger Owen MD, MRCP, FRCPath (UK)
S.T. Pals, MD, PhD (Netherlands)
Marvin Stone, MD (USA)
Marzia Varretoni, MD (Italy)

Registration for this meeting is now closed.

New York 2018 (IWWM-10) was held at the New York Marriott Downtown in New York City.

New York Marriott Downtown

Click here to download our New York City visitor's guide